StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.3
Power Rank trend -> Rising
05/16/2025 16:10:00 EST
Penumbra Inc (PEN)
Industry: Medical Devices
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, PEN has been trading in a range between $299.78 and $270.27 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
PEN is trading below resistance at $303.76, about 8% to the upside. There is support at $273.78 -2% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Penumbra Inc $PEN entered a Green zone 19 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $318.5882, a potential upside of 7.07% from the recent price of 297.55. The stock is trading 4.18% (potential upside) below its 52 week high of $310.00 and 101.05 % (potential downside) above its 52 week low of $148.00 - based on the recent price.
Company Summary
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
News
| Here's Why Penumbra (PEN) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Source: Zacks Investment Research Thu, 15 May 2025 10:56:16 -0400 Sentiment: Positive |
| Here's Why Penumbra (PEN) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Source: Zacks Investment Research Wed, 14 May 2025 10:50:48 -0400 Sentiment: Positive |
| 3 Mid-Cap Medical Stocks Outperforming the Market While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance. Source: MarketBeat Tue, 06 May 2025 12:50:17 -0400 Sentiment: Positive |
| Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference ALAMEDA, Calif. , April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Source: PRNewsWire Tue, 29 Apr 2025 16:30:00 -0400 Sentiment: Neutral |
| Baron Health Care Fund Q1 2025 Top Net Purchases And Sales Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst. Source: Seeking Alpha Tue, 29 Apr 2025 11:45:00 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 310 52 Week Low: 148 Beta: 0.53 50 Day MA: 278.9908 200 Day MA: 240.9592 Earnings / Revenue Trends Qtr Earnings Growth YOY: 2.571 Qtr Revenue Growth YOY: 0.163 Forward PE: 77.5194 Trailing PE: 257.3084